Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin changes in head and neck cancer patients under combined radioimmuno(chemo)therapy with Erbitux
2010-019748-38Phase 4Completed
- Sponsor
- Heidelberg University
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Heidelberg University. Primary endpoint: Rate of radiation dermatitis Grade 3/4. Started Sep 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2010-019748-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019748-38.